Empagliflozin gets PBAC nod for HFpEF
The recommendation for an expanded PBS listing for empagliflozin follows a recent update to the drug's indication.
The PBAC has recommended expanding the PBS listing for empagliflozin to include patients with chronic heart failure and a left ventricular ejection fraction above 40%.
The SGLT-2 inhibitor is already subsidised for heart failure with reduced ejection fraction as an add-on to standard therapy.
If adopted by the Federal Government, the change would bring the PBS listing for 10mg daily empagliflozin (Jardiance) in line with its expanded TGA indication, which covers all patients with symptomatic heart failure.
The PBAC said the drug “provided a statistically significant improvement in efficacy” over standard care for a condition with a “high unmet clinical need for effective treatments”.
